Therapeutic	0	11	O
angiogenesis	12	24	O
:	24	25	O
a	26	27	O
complex	28	35	O
problem	36	43	O
requiring	44	53	O
a	54	55	O
sophisticated	56	69	O
approach	70	78	O
.	78	79	O

Blood	81	86	B-Organism_substance
and	87	90	O
vascular	91	99	B-Multi-tissue_structure
disorders	100	109	O
underlie	110	118	O
a	119	120	O
plethora	121	129	O
of	130	132	O
pathologic	133	143	O
conditions	144	154	O
and	155	158	O
are	159	162	O
the	163	166	O
single	167	173	O
most	174	178	O
frequent	179	187	O
cause	188	193	O
of	194	196	O
human	197	202	B-Organism
disease	203	210	O
.	210	211	O

Ischemia	212	220	O
,	220	221	O
involving	222	231	O
restricted	232	242	O
blood	243	248	B-Organism_substance
flow	249	253	O
to	254	256	O
tissues	257	264	B-Tissue
is	265	267	O
the	268	271	O
most	272	276	O
common	277	283	O
consequence	284	295	O
of	296	298	O
vessel	299	305	B-Multi-tissue_structure
dysfunction	306	317	O
resulting	318	327	O
in	328	330	O
the	331	334	O
disruption	335	345	O
of	346	348	O
oxygen	349	355	B-Drug_or_compound
and	356	359	O
nutrient	360	368	O
delivery	369	377	O
and	378	381	O
the	382	385	O
accumulation	386	398	O
of	399	401	O
waste	402	407	O
metabolites	408	419	O
.	419	420	O

Cells	421	426	B-Cell
cannot	427	433	O
survive	434	441	O
extended	442	450	O
severe	451	457	O
ischemia	458	466	O
but	467	470	O
may	471	474	O
be	475	477	O
able	478	482	O
to	483	485	O
adapt	486	491	O
to	492	494	O
a	495	496	O
moderate	497	505	O
condition	506	515	O
where	516	521	O
diffusion	522	531	O
to	532	534	O
and	535	538	O
from	539	543	O
bordering	544	553	O
nonischemic	554	565	O
regions	566	573	O
sustains	574	582	O
vital	583	588	O
functions	589	598	O
.	598	599	O

Under	600	605	O
this	606	610	O
condition	611	620	O
,	620	621	O
the	622	625	O
secondary	626	635	O
functions	636	645	O
of	646	648	O
effected	649	657	O
cells	658	663	B-Cell
are	664	667	O
likely	668	674	O
to	675	677	O
be	678	680	O
impaired	681	689	O
,	689	690	O
and	691	694	O
a	695	696	O
new	697	700	O
metabolic	701	710	O
equilibrium	711	722	O
is	723	725	O
established	726	737	O
,	737	738	O
determined	739	749	O
by	750	752	O
the	753	756	O
level	757	762	O
of	763	765	O
cross	766	771	O
-	771	772	O
diffusion	772	781	O
and	782	785	O
degree	786	792	O
of	793	795	O
hypoxia	796	803	O
.	803	804	O

In	805	807	O
tissues	808	815	B-Tissue
with	816	820	O
a	821	822	O
normally	823	831	O
high	832	836	O
metabolic	837	846	O
turnover	847	855	O
such	856	860	O
as	861	863	O
skeletal	864	872	B-Tissue
and	873	876	O
cardiac	877	884	B-Tissue
muscle	885	891	I-Tissue
,	891	892	O
even	893	897	O
mild	898	902	O
ischemia	903	911	O
causes	912	918	O
hypoxia	919	926	O
,	926	927	O
acidosis	928	936	O
,	936	937	O
and	938	941	O
depressed	942	951	O
function	952	960	O
(	961	962	O
contractility	962	975	O
)	975	976	O
and	977	980	O
eventually	981	991	O
threatens	992	1001	O
myocyte	1002	1009	B-Cell
viability	1010	1019	O
and	1020	1023	O
organ	1024	1029	B-Organ
function	1030	1038	O
.	1038	1039	O

Ischemic	1040	1048	O
cardiac	1049	1056	B-Tissue
muscle	1057	1063	I-Tissue
is	1064	1066	O
additionally	1067	1079	O
vulnerable	1080	1090	O
because	1091	1098	O
reperfusion	1099	1110	O
is	1111	1113	O
essential	1114	1123	O
for	1124	1127	O
survival	1128	1136	O
but	1137	1140	O
reperfusion	1141	1152	O
itself	1153	1159	O
poses	1160	1165	O
additional	1166	1176	O
stress	1177	1183	O
principally	1184	1195	O
from	1196	1200	O
increased	1201	1210	O
production	1211	1221	O
of	1222	1224	O
free	1225	1229	O
radicals	1230	1238	O
during	1239	1245	O
reoxygenation	1246	1259	O
.	1259	1260	O

The	1261	1264	O
latter	1265	1271	O
effect	1272	1278	O
is	1279	1281	O
called	1282	1288	O
reperfusion	1289	1300	O
injury	1301	1307	O
and	1308	1311	O
can	1312	1315	O
cause	1316	1321	O
as	1322	1324	O
much	1325	1329	O
damage	1330	1336	O
as	1337	1339	O
the	1340	1343	O
ischemia	1344	1352	O
.	1352	1353	O

The	1354	1357	O
treatment	1358	1367	O
possibilities	1368	1381	O
for	1382	1385	O
ischemia	1386	1394	O
-	1394	1395	O
related	1395	1402	O
vascular	1403	1411	O
disease	1412	1419	O
are	1420	1423	O
limited	1424	1431	O
.	1431	1432	O

Lipid	1433	1438	B-Drug_or_compound
/	1438	1439	O
cholesterol	1439	1450	B-Drug_or_compound
-	1450	1451	O
lowering	1451	1459	O
agents	1460	1466	O
,	1466	1467	O
diet	1468	1472	O
and	1473	1476	O
antiplatelet	1477	1489	O
adherence	1490	1499	O
(	1500	1501	O
aspirin	1501	1508	B-Drug_or_compound
)	1508	1509	O
therapy	1510	1517	O
may	1518	1521	O
help	1522	1526	O
slow	1527	1531	O
the	1532	1535	O
progression	1536	1547	O
of	1548	1550	O
vessel	1551	1557	B-Multi-tissue_structure
disease	1558	1565	O
in	1566	1568	O
some	1569	1573	O
instances	1574	1583	O
;	1583	1584	O
but	1585	1588	O
surgical	1589	1597	O
reconstruction	1598	1612	O
may	1613	1616	O
be	1617	1619	O
the	1620	1623	O
only	1624	1628	O
option	1629	1635	O
in	1636	1638	O
advanced	1639	1647	O
stages	1648	1654	O
,	1654	1655	O
and	1656	1659	O
even	1660	1664	O
this	1665	1669	O
is	1670	1672	O
not	1673	1676	O
always	1677	1683	O
an	1684	1686	O
option	1687	1693	O
.	1693	1694	O

An	1695	1697	O
alternative	1698	1709	O
and	1710	1713	O
rather	1714	1720	O
obvious	1721	1728	O
strategy	1729	1737	O
to	1738	1740	O
treat	1741	1746	O
ischemia	1747	1755	O
is	1756	1758	O
to	1759	1761	O
activate	1762	1770	O
endogenous	1771	1781	O
angiogenic	1782	1792	O
or	1793	1795	O
arteriogenic	1796	1808	O
pathways	1809	1817	O
to	1818	1820	O
stimulate	1821	1830	O
revascularization	1831	1848	O
of	1849	1851	O
the	1852	1855	O
tissue	1856	1862	B-Tissue
.	1862	1863	O

The	1864	1867	O
feasibility	1868	1879	O
of	1880	1882	O
such	1883	1887	O
a	1888	1889	O
strategy	1890	1898	O
has	1899	1902	O
now	1903	1906	O
been	1907	1911	O
established	1912	1923	O
through	1924	1931	O
the	1932	1935	O
results	1936	1943	O
of	1944	1946	O
studies	1947	1954	O
over	1955	1959	O
the	1960	1963	O
past	1964	1968	O
decade	1969	1975	O
,	1975	1976	O
and	1977	1980	O
a	1981	1982	O
new	1983	1986	O
discipline	1987	1997	O
called	1998	2004	O
therapeutic	2005	2016	O
angiogenesis	2017	2029	O
has	2030	2033	O
emerged	2034	2041	O
.	2041	2042	O

This	2043	2047	O
review	2048	2054	O
focuses	2055	2062	O
on	2063	2065	O
the	2066	2069	O
application	2070	2081	O
of	2082	2084	O
therapeutic	2085	2096	O
angiogenesis	2097	2109	O
for	2110	2113	O
treating	2114	2122	O
ischemic	2123	2131	O
muscle	2132	2138	B-Organ
disease	2139	2146	O
and	2147	2150	O
includes	2151	2159	O
a	2160	2161	O
critical	2162	2170	O
evaluation	2171	2181	O
of	2182	2184	O
the	2185	2188	O
parameters	2189	2199	O
and	2200	2203	O
limitations	2204	2215	O
of	2216	2218	O
current	2219	2226	O
procedures	2227	2237	O
.	2237	2238	O

The	2239	2242	O
development	2243	2254	O
of	2255	2257	O
this	2258	2262	O
technology	2263	2273	O
has	2274	2277	O
benefited	2278	2287	O
from	2288	2292	O
its	2293	2296	O
application	2297	2308	O
to	2309	2311	O
both	2312	2316	O
peripheral	2317	2327	B-Multi-tissue_structure
and	2328	2331	O
coronary	2332	2340	B-Multi-tissue_structure
artery	2341	2347	I-Multi-tissue_structure
disease	2348	2355	O
and	2356	2359	O
results	2360	2367	O
from	2368	2372	O
both	2373	2377	O
are	2378	2381	O
reviewed	2382	2390	O
here	2391	2395	O
.	2395	2396	O

